TACR1 and hepatoblastoma: Similarly, in a hepatoblastoma xenograft mouse model, treatment with NK-1R antagonist aprepitant at 80 mg/kg/day for 24 days led to a significant reduction in tumor volume and weight, as well as in Ki-67-positive cells [8].